source
- Novartis' pelacarsen fails Phase 3, casting doubt on Lp(a) lowering strategyNovartis announced that its antisense drug pelacarsen failed to meet the primary endpoint in the Phase 3 Lp(a)HORIZON trial. The study was intended to determine whether the drug’s ability to lower…
- Pharvaris reports 83% drop in hereditary angioedema attacks in phase 3 trial, FDA decision pendingPharvaris announced that its oral bradykinin B2 receptor antagonist, deucrictibant, met the primary goal in a second phase 3 study. The trial, called CHAPTER-3, enrolled 85 patients with three for…